- Home
- BRNS vs ACHL Comparison
BRNS vs ACHL Comparison
Compare BRNS & ACHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- ACHL
- Stock Information
- Founded
- BRNS 2016
- ACHL 2016
- Country
- BRNS United Kingdom
- ACHL United Kingdom
- Employees
- BRNS N/A
- ACHL N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- ACHL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BRNS Health Care
- ACHL Health Care
- Exchange
- BRNS Nasdaq
- ACHL Nasdaq
- Market Cap
- BRNS 41.0M
- ACHL 46.8M
- IPO Year
- BRNS 2021
- ACHL 2021
- Fundamental
- Price
- BRNS $1.04
- ACHL $1.14
- Analyst Decision
- BRNS Strong Buy
- ACHL Buy
- Analyst Count
- BRNS 2
- ACHL 2
- Target Price
- BRNS $3.00
- ACHL $4.00
- AVG Volume (30 Days)
- BRNS 46.0K
- ACHL 266.7K
- Earning Date
- BRNS 11-06-2024
- ACHL 11-14-2024
- Dividend Yield
- BRNS N/A
- ACHL N/A
- EPS Growth
- BRNS N/A
- ACHL N/A
- EPS
- BRNS N/A
- ACHL N/A
- Revenue
- BRNS $14,969,000.00
- ACHL N/A
- Revenue This Year
- BRNS $1,805.74
- ACHL N/A
- Revenue Next Year
- BRNS N/A
- ACHL N/A
- P/E Ratio
- BRNS N/A
- ACHL N/A
- Revenue Growth
- BRNS 106.21
- ACHL N/A
- 52 Week Low
- BRNS $0.80
- ACHL $0.63
- 52 Week High
- BRNS $4.16
- ACHL $1.76
- Technical
- Relative Strength Index (RSI)
- BRNS 48.42
- ACHL 55.79
- Support Level
- BRNS $0.91
- ACHL $1.12
- Resistance Level
- BRNS $1.15
- ACHL $1.18
- Average True Range (ATR)
- BRNS 0.15
- ACHL 0.05
- MACD
- BRNS -0.01
- ACHL -0.00
- Stochastic Oscillator
- BRNS 34.96
- ACHL 33.33
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.
About ACHL Achilles Therapeutics plc
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.